RNA-Seq and ribosome profiling data of differentiated TSC2 wild-type and homozygous deletion cell lines treated with mTOR inhibitors (related to Fig. 4). (XLSB 7.52 mb)
An oral mucosa tissue model was treated with 32 ng or 64 ng everolimus, an mTOR inhibitor, for 40 or 60 hours to study the transcriptome changes Everolimust treatment of oral mucosa
Transgenic (Probasin driven Myr-AKT)or wild-type littermates were treated with RAD001 or placebo and sacrificed at 12 and 48 hours following the beginning of treatment Keywords = AKT Prostate RAD001 m
Everolimus (EVL) and Sirolimus (SRL) are potent immunosuppressant agents belonging to the group of mammalian target of rapamycin (mTOR) inhibitors used to prevent transplant rejection. However, some p
